FDA Grants Rare Pediatric Disease Designation to CLR 131 in Treatment of Osteosarcoma

September 21, 2018 – The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to CLR 131 for the treatment of osteosarcoma. CLR 131 has received Rare Pediatric Disease designation in four pediatric cancers: neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, and now osteosarcoma. The FDA grants Rare Pediatric Disease designation for diseases that primarily affect children from birth to 18 years old and fewer than … (leggi tutto)